Fatigue Severity Scale (FSS)

Krupp LB


Basic description

Original 9-item version developed in 1989. A 10-item version including a VAS also exists (Kleinman et al, 2000).


Krupp LB

Sept 11 2000 - Fatigue Severity Scale
To assess the severity of fatigue and its impact on daily living
Therapeutic area
  • Pathological Conditions, Signs and Symptoms
Therapeutic indication


The FSS has been used as a measure of disabling fatigue in a variety of disorders including multiple sclerosis, systemic lupus erythematosus, hepatitis, and chronic fatigue syndrome
Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
38 translation(s)
Bibliographic reference(s) of the original questionnaire

Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123 (PubMed abstract)

Krupp LB, LaRocca NG, Muir J, Steinberg AD. A study of fatigue in systemic lupus erythematosus. J Rheumatol. 1990 Nov;17(11):1450-2 (PubMed abstract)

Krupp LB, Mendelson WB, Friedman R. An overview of chronic fatigue syndrome. J Clin Psychiatry. 1991 Oct;52(10):403-10. Review (PubMed abstract)

Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, Halper J, Johnson B, Morgante L, Grimson R. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995 Nov;45(11):1956-61 (PubMed abstract)

Kleinman L, Zodet MW, Hakim Z, Aledort J, Barker C, Chan K, Krupp L, Revicki D. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res. 2000;9(5):499-508 (PubMed abstract)

Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, et al. Study and Treatment of Lyme Disease (STOP-LD) randomized double masked clinical trial. Neurology 2003;60:1923-1930 (PubMed abstract)

Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002;35:704-8 (PubMed abstract)

Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollack CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two center phase 2 study. J Neurol Neurosurg Psychiatry. 2002; 72:179-183 (Full text article)

Sheean G. Murray N, Rothwell J, Miller D. Thompsom A. An open labeled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain. 1998;121:967-975 (Full text article)

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us